THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

EYLEA HD's success mitigates biosimilar ... and growing the overall franchise by 4% YoY. LIBTAYO globally grew sales to $288.6M, a +23% YoY growth rate. While DUPIXENT sales grew to $3,817M ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

The combination also achieved a 43% response rate compared with 23% for chemo alone, with a duration of response of 16 months versus seven months, respectively. Libtayo – the sixth PD-L/PD-L1 ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...

Objective response rate (ORR) was 31% among 84 Libtayo-treated patients with a median follow-up of 15 months. This included a 6% (n=5) complete and 25% (n=21) partial response rate. This is an ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...